Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

21.96 +0.27 (+1.22%)

Streaming Delayed Price Updated: 2:02 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >

Roivant Signals Major Pipeline Momentum With Accelerated Timelines ↗

December 11, 2025

Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.

Via Benzinga

Roivant (ROIV) Q2 2026 Earnings Call Transcript ↗

November 27, 2025

Roivant (ROIV) Q2 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

Looking Into Roivant Sciences Ltd's Recent Short Interest ↗

November 11, 2025

Via Benzinga

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Preview For Roivant Sciences ↗

November 07, 2025

Via Benzinga

A Glimpse of Roivant Sciences's Earnings Potential ↗

August 08, 2025

Via Benzinga

What Does the Market Think About Roivant Sciences? ↗

July 23, 2025

Via Benzinga

6 Analysts Assess Roivant Sciences: What You Need To Know ↗

September 18, 2025

Via Benzinga

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17 ↗

September 17, 2025

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study,...

Via Stocktwits

Why Roivant Sciences Stock Is Soaring Today ↗

September 17, 2025

The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug.

Via The Motley Fool

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial ↗

September 17, 2025

Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results.

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

September 17, 2025

Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Peering Into Roivant Sciences's Recent Short Interest ↗

June 25, 2025

Via Benzinga

Roivant Sciences's Earnings Outlook ↗

May 28, 2025

Via Benzinga

Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗

September 17, 2025

Via Benzinga

Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease ↗

September 17, 2025

The company is working on a treatment for an autoimmune disease that affects the skin and muscles.

Via Investor's Business Daily

Why Roivant Sciences Stock Bounced Back on Tuesday ↗

August 12, 2025

Investors were in a forgiving mood after Monday's dispiriting earnings release.

Via The Motley Fool

Why Roivant Sciences Stock Was Slipping on Monday ↗

August 11, 2025

The distinctive biotech wasn't a sector favorite as the trading week began.

Via The Motley Fool

Roivant Sciences Q3 Earnings Assessment ↗

February 10, 2025

Via Benzinga

Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports

August 11, 2025

Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings....

Via MarketMinute

Topics Economy Stocks

Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What's Driving Markets Thursday? ↗

May 29, 2025

Wall Street hovered slightly higher by midday Thursday, giving up a chunk of strong overnight gains in futures markets that were triggered by a federal court ruling suspending a large portion of...

Via Benzinga

Topics Government

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Earnings Scheduled For May 29, 2025 ↗

May 29, 2025

Via Benzinga

Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift ↗

April 21, 2025

The company is getting a new chief executive and a new chief financial officer amid sweeping changes.

Via Investor's Business Daily

Topics Government

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data ↗

March 19, 2025

Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.

Via Benzinga

Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled. ↗

March 19, 2025

The companies reported positive results for their lead asset in patients with two rare diseases.

Via Investor's Business Daily

Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday? ↗

February 10, 2025

Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while...

Via Benzinga

Topics Government World Trade

Roivant Sciences Tops Q3 Expectations ↗

February 10, 2025

Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline.

Via The Motley Fool

Earnings Scheduled For February 10, 2025 ↗

February 10, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.